View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
July 10, 2019

BioNTech secures $325m in series B funding

German company BioNTech has raised $325m in a series B financing round to support further development of its therapeutics pipeline and manufacturing infrastructure.

German company BioNTech has raised $325m in a series B financing round to support further development of its therapeutics pipeline and manufacturing infrastructure.

The funding round was upsized and led by Fidelity Management & Research.

Fidelity was joined by Redmile Group, Invus, MiraeAsset Financial Group, Platinum Asset Management, Jebsen Capital, Steam Athena Capital, BVCF Management and the Struengmann Family Office.

Two-thirds of the latest capital was said to have been contributed by new investors.

BioNTech CEO and co-founder Ugur Sahin said: “With our ongoing focus on bringing together transformative technologies, it is exciting to have the support from high-technology investors who see the accelerating convergence of biology with bioinformatics, robotics and artificial intelligence as an opportunity to develop more precise, efficacious and cost-effective individualised immunotherapies.”

Founded in 2008, BioNTech is engaged in the development of patient-specific immunotherapies for cancer and other serious diseases.

Its pipeline consists of individualised mRNA-based drug candidates, chimeric antigen receptor T cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules.

BioNTech entered partnerships with multiple companies, including Eli Lilly, Genmab, Sanofi, Bayer Animal Health, Roche Group subsidiary Genentech and Genevant.

The company also collaborated with Pfizer in August last year for the development of mRNA-based vaccines to prevent influenza.

Last January, the company secured $270m in a series A funding round led by Redmile Group.

Proceeds from this funding round were used to advance seven product candidates in eight ongoing clinical trials and establish a second GMP manufacturing licence to generate its neoantigen specific immunotherapies.

The company also used funds to expand its antibody platform. Recently, BioNTech acquired a Phase I/IIa pancreatic cancer programme from MabVax Therapeutics.

At the same time, BioNTech established a research and development facility in San Diego, California, US.

Related Companies

Free Report

What’s missing from your IPO industry assessment?

IPO activity all but stopped in 2020, as the investment community grew wary of the effects of COVID-19 on economies. No matter how deserving a business was of flotation, momentum was halted by concerns of when a ‘new normal’ of working patterns and trade would set in. Recently, sentiment has changed. Flotations picked up again during the second half of 2021, and now in 2022 the mood is decidedly optimistic. Business leaders have their eyes on fast rebounding economies, buoyant market indices and the opportunity once again to take their businesses public. As a result, global IPOs are expected to hit back this year. With GlobalData’s new whitepaper, ‘IPOs in Consumer and Retail: 5 must-include elements for your prospectus industry report’, you can explore exactly what is needed in the essential literature. GlobalData’s focus lies in the critical areas to get right:
  • Macroeconomic and demographic environment
  • Consumer context
  • Industry environment
  • Competitive environment
  • Route to market
Interested to learn more about what to include in your IPO Industry Assessment report? Download our free whitepaper.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy